LOGIN  |  REGISTER

Genelux (NASDAQ: GNLX) Stock Quote

Last Trade: US$6.43 0.41 6.81
Volume: 66,217
5-Day Change: 3.71%
YTD Change: -54.10%
Market Cap: US$171.810M

Latest News From Genelux

Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company,... Read More
Expanded executive team as Lourie Zak appointed Chief Financial Officer Extended clinical focus on systemic administration in small cell lung cancer $29.9 million in cash and equivalents WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business... Read More
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company’s 2023 Inducement Plan, including an... Read More
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11 t h , 2023. The Company will also attend virtual... Read More
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023. "I am excited to welcome Lourie to Genelux as our new Chief Financial Officer," said Thomas Zindrick , President, Chairman and CEO of Genelux. "Lourie’s extensive experience... Read More
Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index Publication of VIRO-15 Phase 2 data in JAMA Oncology $51 Million raised after closing of two private placements in Q2, totaling $65 million raised in the first half of 2023 Current cash and cash commitments expected to fund operations into Q1 2026 WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:... Read More
WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023. The conversation with Kaveri Pohlman, PhD, Director and BTIG... Read More
WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of two new members to its leadership team. Joseph Cappello, Ph.D ., who previously served as the Company’s Vice President of Pharmaceutical Development, has been promoted to Chief Technical Officer. Tony Yu, Ph.D.,... Read More
Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density and increase in immune cell density, confirming the mechanism of action of both direct cytotoxic and immune-activating effects.... Read More
V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral immunotherapy) and TVAX Immunotherapy ® (vaccine-enhanced adoptive T cell therapy). The patent expiry for the combination, prior to any patent term extension, will be in 2036. WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE... Read More
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.... Read More
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, before deducting offering expenses payable by Genelux. The financing was led by existing investors and no... Read More
Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responses Generated promising progression-free survival Demonstrated clinical reversal of platinum resistance and refractoriness Phase 3 OnPrime/GOG-3076 randomized active-controlled registrational trial in collaboration with GOG Foundation/Partners is currently enrolling... Read More
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before deducting offering expenses payable by Genelux. Proceeds from the private placement, combined with the current... Read More
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced that it will ring the Nasdaq Stock Market (“Nasdaq”) opening bell on... Read More
Cue Biopharma

COPYRIGHT ©2023 HEALTH STOCKS HUB